Background: Hyperglycemia is associated with hemodynamic changes in type 1 diabetes (DM),
INTRODUCTION:
Hyperglycemia plays a critical role in the pathogenesis of renal and systemic vascular complications in type 1 diabetes mellitus (DM), in part by promoting many of the early, permissive hemodynamic changes characteristic of DM (46).
In early type 1 DM, hyperglycemia is associated with reduced renal vascular resistance (RVR) and renal hyperfiltration, which may promote susceptibility to kidney injury mediated by intraglomerular hypertension (6) . Hyperglycemia-mediated renin angiotensin system (RAS) activation is also associated with renal hyperfiltration through arterial vasoconstriction (29). In older subjects with DM and clinical evidence of nephropathy, RVR is increased which has also been associated with vascular injury and adverse renal outcomes (26, 36) .
In early, uncomplicated type 1 DM, vascular resistance in the systemic circulation is also low, resulting in systemic hyperperfusion; this vasodilated systemic phenotype may reverse with age (50) , although the independent effects of age on hemodynamic responses have not been well elucidated in patients with and without diabetes. Diabetic systemic circulatory changes have also been attributed to hyperglycemia, which quenches nitric oxide activity, promotes the deposition of advanced glycation end-products and accelerates the vascular senescent effects of angiotensin (Ang II) (11, 17, 24, 26, 41, 42) . Hemodynamic consequences of these pathways include increased arterial stiffness, endothelial dysfunction and hypertension (3, 13) . These hyperglycemia-dependent and independent hemodynamic alterations have been implicated in the pathogenesis of microvascular and macrovascular complications associated with DM. Ang II is similarly associated with deleterious renal and systemic hemodynamic responses in animals and humans (11, 17, 24, 26, 41, 42) . Advancing age may potentiate and exaggerate these systemic and renal hemodynamic consequences of hyperglycemia and the renin angiotensin system (51) .
For example, femoral intra-arterial administration of Ang II is associated with exaggerated local declines in blood flow in older non-DM subjects compared with young individuals (53) . In contrast, the effect of Ang II on systemic blood pressure non-DM subjects may be ageindependent (19) . In humans with type 1 DM, previous work has suggested that type 1 DM accelerates vascular aging (18, 41, 45) . The effect of age on dynamic renal hemodynamic and peripheral vascular responses to factors that may promote diabetic vascular dysfunction, including systemic administration of Ang II or clamped hyperglycemia, is unknown.
Accordingly, the goal of this study was to examine the effect of age on the acute renal hemodynamic and systemic vascular responses to the induction of clamped hyperglycemia and an infusion of Ang II. In the primary analysis, we divided subjects with uncomplicated type 1 DM into two groups on the basis of age: adolescent/young DM adults (age range 12-20) and older DM adults (age range 32-56). We hypothesized that age would be a determinant of the acute renal and systemic hemodynamic responses to hyperglycemia and an infusion of Ang II, and that these responses would be exaggerated in older subjects. Due to the important effect of diabetes duration on vascular dysfunction, we also analyzed a subgroup of the diabetic cohort that was matched for duration of diabetes (27) . Finally, we compared a cohort of healthy non-DM subjects who had been administered an Ang II infusion in our laboratory using similar protocols (mean age 26, age range 18-40 years) (2, 30, 31) , and compared them to age-matched subjects from the diabetes cohort (mean age 26, age range 16-42 years) to elucidate interactions between age and diabetes status.
MATERIALS and METHODS:
In the primary analysis, we included 66 men and women with type 1 DM. Inclusion criteria included the following factors: duration of type 1 DM ≥5 years, blood pressure <140/90, and no history of renal disease, microalbuminuria or macrovascular disease. We divided subjects into 2 groups, adolescent/young adults (n=34) and older adults (n=32). To be eligible, adolescent/young adult subjects were required to be at a minimum of Tanner stage 2 of puberty.
No subjects were taking angiotensin receptor blockers or angiotensin converting enzyme inhibitors. Oral contraceptive and hormone replacement pill users and postmenopausal females were excluded. Female subjects were studied during the follicular phase of the menstrual cycle, determined by counting days and measuring 17ß-estradiol levels. To account for the effects of diabetes duration on vascular function, we performed a second analysis in 20 adolescent/young adult and 20 older adult DM subjects who were matched for their duration of diabetes. We also compared the hemodynamic responses of our DM subjects to an historical cohort of healthy nondiabetic subjects who had been administered an Ang II (2.5 or 3 ng/kg/min) in our laboratory (n=97) (2, 30, 31) and compared them to age-matched subjects from the diabetic cohort (n=42)
to elucidate interactions between age and diabetes status. The local Research Ethics Board at the University Health Network and Hospital for Sick Children (Toronto, Canada) approved the protocol and all patients gave informed consent. In subjects under the age of 18, subjects provided assent and parents signed informed consent documents in compliance with Hospital for Sick Children Research Ethics Board policies and procedures.
Experimental Design
In the DM cohort, subjects adhered to a sodium-replete (minimum sodium intake 140-160 mmol/day) and moderate protein (<1.5 g/kg/day) diet during the 7-day period before each experiment (Table 1 ) (9) . Dietary adherence was assessed using the mean of two timed urine collections obtained in the 7-day pre-study period and no subjects were excluded because of dietary non-adherence. A sodium-replete diet was used to avoid effective circulating volume contraction and RAS activation (9) . After admission to the Renal Physiology Laboratory, euglycemic (4-6 mmol/L) and hyperglycemic (9-11 mmol/L) conditions were maintained by a modified glucose clamp technique on two consecutive days for approximately 6 hours preceding and during all investigations, as described previously (9) . In the left arm, a 16-gauge peripheral venous cannula was inserted into the antecubital vein for infusion of glucose and insulin and a second cannula was inserted for blood sampling more distally. Blood glucose was measured every 10-15 minutes and the insulin infusion was adjusted to maintain the desired glycemic level.
Following the glucose clamp, right radial artery waveforms were recorded with a highfidelity micromanometer (SPC-301, Millar Instruments) and using the validated transfer function, corresponding central aortic pressure waveform data were generated (SphygmoCor, AtCor Medical Systems Inc., Sydney, Australia). Augmentation index, an estimate of systemic arterial stiffness was calculated as the difference between the second systolic peak and inflection point, expressed as a percentage of the central pulse pressure corrected to an average heart rate of 75 beats per minute. The aortic pulse wave velocity (PWV) was measured using the same device by sequentially recording ECG-gated right carotid and radial artery waveforms. The inter-operator variability and reproducibility of the augmentation index have been validated to be 0.4±6.4%. Our group has published and validated the use of the SphygmoCor device (8, 34) .
Renal hemodynamic function tests were performed immediately after arterial stiffness data were collected. A third intravenous line was inserted into the arm contralateral to the insulin infusion and was connected to a syringe infusion pump for infusions of inulin and paraaminohippurate (PAH). Peripheral blood pressure was measured in the right brachial artery with an automated DINAMAP® sphygmomanometer (Critikon, Florida, USA) prior to each blood sample throughout the study. After collecting blood for inulin and PAH blank, a priming infusion containing 25% inulin (60 mg/kg) and 20% PAH (8 mg/kg) was administered.
Thereafter, inulin and PAH were infused continuously at a rate calculated to maintain their respective plasma concentrations constant at 20 and 1.5 mg/dl. Subjects remained supine at all times. After a 90 minute equilibration period, blood was collected for inulin, PAH and hematocrit (HCT); GFR and effective renal plasma flow (ERPF) were estimated by steady state infusion method for inulin and PAH, respectively, as described previously (9) . All experiments were performed in the same warm (25°C), temperature-controlled room and in a dark, quiet environment (9).
After baseline measurements were obtained Ang II was infused intravenously on the euglycemic day only (3 ng/kg/min). The solution of Ang II (Clinalfa, Läufelfingen, Switzerland -51.2 μg/vial) was prepared by dissolving the diluent in normal saline to produce a concentration of 100 μg/ml. Twenty-two mls normal saline were then added to 0.22 mls Ang II solution to produce a concentration of 400 ng/ml. Blood was collected once during each Ang II infusion period for HCT, inulin and PAH. An identical study protocol was followed in non-DM control subjects, except that clamped hyperglycemia was not induced and Ang II was infused at a dose of either 2.5 (n=61) or 3 ng/kg/min (n=36) (2, 30, 31) . Arterial stiffness was not assessed in non-DM individuals.
Sample Collection and Analytical Methods:
Blood samples collected for inulin and PAH determinations were immediately centrifuged at 3000 rpm for 10 minutes at 4° C. Plasma was separated, placed on ice, and then stored at -70° C before the assay. Inulin and PAH were measured in serum by colorimetric assays using anthrone and N-(1-naphthyl) ethylenediamine respectively. The effect of hyperglycemia on anthrone was corrected for using the blank subtraction (pre-infusate sample) method (7, 9) . Filtration fraction analysis. On the day of analysis plasma samples were extracted on phenylsilysilica columns. A competitive radioimmunoassay kit supplied by Buhlmann Laboratories AG (Switzerland) was used to measure the extracted Ang II. Aldosterone was measured by radioimmunoassay, using the Coat-A-Count system (9). Urinary albumin excretion rate was determined from two timed urine collections. Urinary albumin concentration was determined by immunoturbidimetry and HbA1C was measured by high-performance liquid chromatography (9) .
Statistical Analysis
Descriptive statistics were used to compare baseline clinical and demographic characteristics. Between group comparisons in baseline parameters in the younger vs. older adult subject groups were made using parametric methods (unpaired t-test). Between group differences in renal hemodynamic responses to hyperglycemia and Ang II were determined by repeated measures analysis of variance (ANOVA). We controlled for baseline between group differences in hemodynamic parameters by entering these factors into a multivariate stepwise regression analysis, and controlled for the effects of gender and BMI on renal function by including these factors in the statistical model (1, 10, 16, 31) . In the primary analysis, we included the entire sixty-six member cohort and did not correct for differences in diabetes duration. In a separate analysis, we individually matched 20 younger DM subjects with 20 older DM subjects for diabetes duration to account for possible effects of disease duration on vascular function (26, 36) and repeated between group analyses. Only 20 of the younger DM patients were matched with 20 older DM subjects because the difference in duration of diabetes for remaining subjects was greater than 2 years. Finally, we compared the effect of age on hemodynamic responses of diabetic subjects to an historical control group of 97 healthy non-DM subjects; we used a repeated measures ANOVA analysis to examine the interaction between age, hemodynamic parameters and Ang II responses. All statistical analyses were performed using the statistical package SPSS (SPSS for graduate students, Version 14.0).
RESULTS: Baseline demographic parameters
As expected in the primary analysis, the study groups differed in age and diabetes duration but exhibited no significant differences in HbA1C, BMI or weight (Table 1) older DM adults.
The cohort of non-DM control subjects consisted of men and women who were prepared in a similar manner, with a controlled sodium and protein diet (Table 1 ) (30) . They were normotensive, normoalbuminuric and normoglycemic. Mean estradiol levels were consistent with the late follicular phase of the menstrual cycle (Table 1) .
Effect of age on renal and systemic hemodynamic responses to acute hyperglycemia in DM subjects
During baseline clamped euglycemia, older DM adults exhibited higher DBP, MAP, arterial stiffness and RVR and lower GFR, ERPF and RBF values compared with adolescent/young DM adults ( Table 2 , ANOVA interaction term p=0.0001 for between-group differences). During clamped hyperglycemia, SBP, DBP, MAP, arterial stiffness, and RVR were higher and ERPF, RBF and GFR were lower in older DM adults ( Table 2 , ANOVA interaction term p≤0.001 for between-group differences).
Induction of clamped hyperglycemia was associated with significant increases in SBP, DBP, MAP, radial augmentation index, GFR and RVR in older DM adults, whereas only GFR increased in adolescent/young DM adults (Table 2) . Between group differences in blood pressure, radial augmentation index and RVR responses to clamped hyperglycemia were also significant (p≤0.036, Table 2 ). In a multivariate regression analysis controlled for gender, BMI, baseline differences in blood pressure and renal function, age was positively correlated with the RVR response to clamped hyperglycemia (adjusted r=0.551, p=0.002).
Effect of age on renal and systemic hemodynamic responses to Ang II in DM subjects
Infusion of Ang II resulted in exaggerated SBP, DBP, MAP and RVR responses in older DM adults compared to adolescent/young adult DM subjects ( 
Effect of age on renal and systemic hemodynamic responses to Ang II in non-DM subjects and an age-matched cohort of type 1 DM subjects
The relationship between age and systemic blood pressure and renal hemodynamic function was also examined in an historical control group who underwent an Ang II infusion protocol in our laboratory after a controlled sodium and protein diet. When analyzed in intervals of 5 years, there were significant interactions between age group and baseline DBP, MAP, ERPF, GFR and RBF and between age and SBP, MAP, RVR responses to Ang II in the DM cohort (Table 4 , all ANOVA interaction terms p≤0.018). In contrast, age was not associated with systemic blood pressure or renal hemodynamic function or Ang II responses in non-DM healthy control subjects (Table 4) .
Effect of age on renal and systemic hemodynamic responses to clamped hyperglycemia and Ang II in diabetic subjects matched for diabetes duration
In the subgroup analysis, the baseline characteristics were similar in the two groups of DM subjects matched for diabetes duration ( Table 5 ). The duration-matched subgroups demonstrated similar differences to those seen in the larger cohort in baseline systemic blood pressure, arterial stiffness and renal hemodynamic parameters during clamped euglycemia and hyperglycemia ( Table 6 ). The changes in systemic blood pressure, arterial stiffness and renal hemodynamic function in response to clamped hyperglycemia were exaggerated in the older adults compared to the duration-matched adolescent/young adult cohort (Table 6 , ANOVA interaction term p≤0.001 for between-group differences). The systemic and renal hemodynamic responses to Ang II were also exaggerated in older adult subjects (Table 7 , ANOVA interaction term p≤0.001 for between-group differences).
DISCUSSION:
The risk of reaching clinical endpoints such as albuminuria or a decline in renal function increases with age in subjects with DM (26, 32, 36) . Accordingly, in our primary analysis, we examined the effect of age on the renal hemodynamic and systemic vascular responses to clamped hyperglycemia and an infusion of Ang II in subjects with uncomplicated type 1 DM.
Due to the important effect of diabetes duration on hemodynamic parameters, we also matched the groups for diabetes duration in a secondary analysis. Our major findings in the primary analysis were: 1) Older age was associated with exaggerated renal hemodynamic, systemic blood pressure and arterial stiffness effects in response to clamped hyperglycemia; 2) Ang II infusion was also associated with augmented renal and systemic vasoconstriction effects in older adults compared with adolescent/young adults with type 1 DM. These results were similar in the secondary, duration-matched analysis involving diabetic participants. No interactions between age and hemodynamic function were observed in the non-DM control subjects.
Our first major finding was that older age was associated with exaggerated renal and systemic responses to acute clamped hyperglycemia. Hyperglycemia is associated with an adverse hemodynamic profile, including vasoconstriction in isolated aortic rings, increased arterial stiffness and endothelial dysfunction in studies of experimental and clinical DM (3, 11, 13, 17, 24, 26, 41, 42) . In experimental models of early DM, moderate hyperglycemia is associated with a rise in intraglomerular pressure, leading to hyperfiltration and renal injury; a similar sequence of events may occur in humans (29, 46). Hyperglycemia has similar deleterious effects in the systemic circulation, leading to vasoconstriction and an increase in arterial stiffness (13). The rise in systemic blood pressure, arterial stiffness and renal vasoconstriction in older DM adults in response to clamped hyperglycemia was exaggerated compared to younger DM members of the cohort, and this effect remained significant even when older adult and adolescent/young adult DM subjects were matched for duration of diabetes. These findings suggest that age is an important determinant of renal and systemic hemodynamic function in humans with type 1 DM, prior to the onset of clinical complications.
Our second major finding was that older age was a determinant of an exaggerated systemic blood pressure and renal hemodynamic responses to infused Ang II in subjects with type 1 DM. These relationships remained significant in the diabetic group after matching subjects for duration of diabetes. In addition, the multivariate analysis confirmed that there was an independent effect of age on renal and systemic hemodynamic responses to Ang II in the diabetic cohort. When diabetic subjects were compared with a cohort of healthy non-DM control subjects, age-related effects were observed only in the cohort with DM. Consistent with previous reports was the observation that age was not associated with baseline renal or systemic vascular function or with responses to Ang II in the healthy non-DM control subjects (19) . Agerelated hemodynamic changes have been previously described in humans with uncomplicated type 1 DM, including higher SBP and lower DBP measurements compared with age-matched controls, leading to a rise in pulse pressure (18, 41) . These previous observational studies are consistent with our findings, since SBP was higher and DBP lower in the 2 youngest groups of DM vs. control subjects. Although our study did not define the mechanisms responsible exaggerated Ang II responses in older diabetic subjects, the augmented response may have been due to Ang II type 1 receptor upregulation, which can increase Ang II sensitivity in humans (31, 51) . AT1 receptor upregulation, which has been observed in aging human vascular tissue, may have been due to the observed declines in circulating RAS mediators, or DM-related increased AT1 receptor mRNA expression and signalling (21, 47, 51) . Alternatively, increased renal and systemic hemodynamic responses in the older DM adults may have been due to secondary factors, such as enhanced stimulation of endothelin release, generation of reactive oxygen species, or the quenching of NO (46). These factors may contribute to age-related changes in vascular function in experimental models and in healthy humans and may contribute to what has been referred to as "accelerated vascular aging" in type 1 DM (17, 18, 24, 41, 42) . The increased sensitivity to Ang II in older adult subjects may partially explain the association between age and vascular complications in diabetic subjects, because Ang II is a trophic hormone that contributes to the development of glomerulosclerosis and vascular stiffness (5, 8, 33, 38, 46) . The augmented Ang II responsiveness in the older diabetic adult group also suggests a possible mechanism for the differences in hyperglycemia-induced hemodynamic effects: high glucose is associated with RAS activation, including upregulation of AT1 receptor mRNA expression in glomerular tissue, resulting in vascular proliferation (47, 54) .
Although we have attributed Ang II-induced changes in renal hemodynamic function (rise in RVR and FF, with declines in ERPF and RBF) to direct renal effects of Ang II, renal autoregulation, independent of Ang II, may play an important role (9, 29). For example, Ang II increased blood pressure, which is predicted to lead to a rise in pre-glomerular resistance (29).
However, the dramatic rise in FF suggests that post-glomerular resistance also increased following infusion of Ang II. Experimental data support that concept of greater sensitivity to
Ang II in the post-glomerular circulation, suggesting that the exaggerated renal hemodynamic effect in older adults was largely on the basis of direct, intrarenal Ang II effects rather than indirect autoregulatory pathways (29).
Our finding that the older DM subjects exhibited evidence of renal and systemic vasoconstriction under baseline euglycemic and hyperglycemic conditions compared with adolescent/young DM adults is supported by previous experimental data and in human studies involving participants with chronic kidney disease (26, 28) . Arterial stiffness was also higher in older subjects. Augmentation index rose further under the influence of clamped hyperglycemia in older diabetic subjects, which has been attributed to acute effects on vascular smooth muscle cells (13). Several neurohormonal factors may be responsible for renal and systemic vasoconstriction in older diabetic subjects. First, under the influence of chronic hyperglycemia, the RAS, sympathetic nervous system and reactive oxygen species are activated, while the bioavailability of important vasodilators, such as nitric oxide (NO), is reduced, resulting in increased RVR and a rise in systemic blood pressure (28, 43) . Interestingly, circulating levels of components of the RAS were lower in the older cohort. Although this may appear paradoxical, activation of the intrarenal RAS with low circulating levels of RAS mediators is typical of DM (40) . This observation is also consistent with previous work which demonstrated lower levels of circulating components of the RAS in older individuals compared with younger individuals with and without hypertension (14, 15, 20, 25, 35, 37, 44, 48, 49, 52) . The reasons for this age-related decline in circulating RAS mediators are not well understood, and have been associated with age-related increases in blood pressure and arterial stiffness, and diminished baroreflex sensitivity (25, 48) . In spite of lower levels of circulating RAS mediators, the renal vasoconstriction and higher blood pressure profile in older DM adults suggest an increase in the activity of vasoconstrictors relative to vasodilators, possibly at the tissue level (26, 28, 36) .
Lower circulating RAS mediators may also have influenced Ang II responsiveness through AT1
receptor upregulation, thereby increasing vascular smooth muscle responsiveness to Ang II administration (21, 47) . When treated as a continuous variable, age correlated with systemic blood pressure, arterial stiffness and renal vasoconstrictive (RVR) responses to clamped hyperglycemia and infused Ang II, supporting our conclusion that age is an important determinant of vascular function in subjects with uncomplicated type 1 DM.
This set of experiments has important limitations. Previous work has suggested that in the absence of nephropathy after a diabetes duration of >20 years, the subsequent risk of developing nephropathy is <1%/year (39) . The older diabetic adult group may therefore not be generalizable to many older subjects with type 1 DM, since our inclusion criteria stipulated that participants had no complications. While the members of this cohort may never develop diabetes-related complications, the goal of this study was not to examine complication rates or risk. Instead, the aim was to elucidate factors that may predispose to renal and systemic vascular injury prior to the onset of clinical disease. Similarly, our findings in healthy non-DM controls cannot be generalized to individuals over the age of 40, who may exhibit age-related vascular changes. Second, estrogen has important effects on vascular and renal function, which may have in part accounted for differences between the older adult and adolescent/young adult female members of the cohort. It is unlikely that hormonal status played an important role in this set of experiments, since circulating estrogen levels were similar and because we included similar
proportions of men and women in each of the groups. Another parameter that can impact renal function is long-term glucose control. HbA1c was measured in both groups and was similar and therefore it is unlikely that this factor contributed to between-group differences. Last, some studies have suggested that older age at onset of type 1 DM, particularly after puberty, contributes to the later development of complications (23) . In the secondary analysis, study groups were matched for diabetes duration by study design and not for age at diagnosis. Since the association between age at diagnosis and risk of complications is inconsistent, it is unlikely that diagnosis before or after puberty played an important role compared to the dramatic effect of age (12).
In conclusion, age is an independent predictor of acute hemodynamic responses to clamped hyperglycemia and Ang II in subjects with uncomplicated type 1 DM. Our findings also highlight a possible physiological interaction between age and factors that may contribute to the pathogenesis of early diabetic vascular dysfunction.
PERSPECTIVES AND SIGNIFICANCE:
Although aging is an important non-modifiable risk factor for cardiovascular disease in patients with and without diabetes, the mechanisms underlying this association are complex, and not well defined. Age may independently contribute to potentially deleterious hemodynamic responses to known mediators of end organ injury in diabetes, including hyperglycemia and Ang II. The interaction between age and diabetes on systemic and renal hemodynamic function has not been rigorously studied in a controlled interventional physiology laboratory setting. Our aim was therefore to determine if factors that cause vascular senescence in animal models are associated with increasing age in humans. To elucidate the independent effects of age on hemodynamic function in type 1 DM, we have studied the systemic and renal hemodynamic profile of a group of subjects with uncomplicated type 1 DM in a controlled physiology laboratory environment. We also determined the effects of age on hemodynamic responses to clamped hyperglycemia and Ang II infusion, which are physiological stimuli known to contribute to long-term risk of vascular injury in subjects with DM. We have found that in this homogenous cohort of normotensive, normoalbuminuric subjects with type 1 DM, dynamic renal and systemic vascular responses are independently influenced by age. The age-dependent changes in Ang II-responsiveness were not observed in our historical cohort of healthy nondiabetic individuals (19) . Experimental models have identified a variety of factors that may be responsible for augmented Ang II effect in DM, including AT1 receptor expression and activity and bioactivity of endothelin and nitric oxide pathways (4, 21, 22, 30, 47) . Whether or not these factors are responsible for age-related effects in humans with DM requires future investigation.
Our results suggest that age is independently associated with augmented hemodynamic responsiveness to clamped hyperglycemia and infusion of Ang II. Future translational physiology experiments in humans with DM should consider the effect of age on hemodynamic responses.
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